Herrling hints Glivec verdict may impact innovator India investments
This article was originally published in Scrip
Executive Summary
Days ahead of a Supreme Court verdict on the crucial and much publicized Glivec (imatinib mesylate) case in India, Novartis seems to be expecting an unfavourable outcome given the backdrop of a series of patent related set-backs for innovator firms. And there has been a broad hint that the outcome of the case could steer Novartis and other firms away from using India as a research base.